Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study
Jeanne Tie, Yuxuan Wang, Joshua Cohen, Lu Li, Wei Hong, Michael Christie, Hui Li Wong, Suzanne Kosmider, Rachel Wong, Benjamin Thomson, Julian Choi, Adrian Fox, Kathryn Field, Matthew Burge, Jenny Shannon, Dusan Kotasek, Niall C Tebbutt, Christos Karapetis, Craig Underhill, Andrew Haydon Show all
PLOS MEDICINE | PUBLIC LIBRARY SCIENCE | Published : 2021
BACKGROUND: In patients with resectable colorectal liver metastases (CRLM), the role of pre- and postoperative systemic therapy continues to be debated. Previous studies have shown that circulating tumor DNA (ctDNA) analysis, as a marker of minimal residual disease, is a powerful prognostic factor in patients with nonmetastatic colorectal cancer (CRC). Serial analysis of ctDNA in patients with resectable CRLM could inform the optimal use of perioperative chemotherapy. Here, we performed a validation study to confirm the prognostic impact of postoperative ctDNA in resectable CRLM observed in a previous discovery study. METHODS AND FINDINGS: We prospectively collected plasma samples from patie..View full abstract
Awarded by Victorian Cancer Agency
Awarded by National Institutes of Health
This work was supported by Victorian Cancer Agency (CRF14007 to JT), the Virginia and D.K. Ludwig Fund for Cancer Research (PG), the National Institutes of Health (P50-CA062924, CA06973, CA176828, and CA210170 to BV) and the John Templeton Foundation (CT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.